Supernus Pharmaceuticals (SUPN) Total Debt (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 9 years of Total Debt data on file, last reported at $31.1 million in Q4 2025.

• Total Debt for Q4 2025 came in at $31.1 million, down 34.41% year-over-year; the trailing twelve-month figure through Dec 2025 was $31.1 million (down 34.41% YoY), and the FY2025 annual result was $31.1 million, down 34.41% from the prior year.
• Total Debt climbed to $31.1 million in Q4 2025 per SUPN's latest filing, from $11.2 million in the prior quarter.
• Over five years, Total Debt peaked at $424.1 million in Q4 2021 and troughed at $11.2 million in Q3 2025.
• A 5-year average of $77.9 million and a median of $46.2 million in 2023 frame the typical range for Total Debt.
• On a YoY basis, Total Debt climbed as much as 1603.1% in 2022 and fell as far as 95.02% in 2022.
• A 5-year view of Total Debt shows it stood at $424.1 million in 2021, then sank by 95.02% to $21.1 million in 2022, then soared by 146.54% to $52.1 million in 2023, then retreated by 9.08% to $47.3 million in 2024, then tumbled by 34.41% to $31.1 million in 2025.
• Business Quant data shows SUPN's Total Debt at $31.1 million in Q4 2025, $11.2 million in Q3 2025, and $30.0 million in Q1 2025.